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Active hepatitis B vaccination of dialysis patients and medical staff. One
hundred six patients with terminal renal insufficiency and 29 medical
personnel were given three doses of hepatitis B vaccine at an interval of
0, 1, and 6 months (Merck, Sharp and Dohme, West Point, Pennsylva-
nia, part of a joint study no. 649). Chronic hemodialysis patients (N =
99) received 40 g vaccine (V) i.m. Uremic patients, who were just
about to start chronic dialysis treatment (N = 7), were given 40 g V,
and at the first vaccination 3 ml hyperimmune globulin (HBIG) in
addition, The medical personnel was alternately vaccinated with 20 sgV (N = 8), 40 g (N = 11), 40 g V, and 3 ml HBIG at the first
vaccination (N = 10). After 12 months, 50% of the male dialysis
patients, 66% of the female dialysis patients, and 95% of the medical
staff developed anti-HBs antibodies. The anti-HBs titer of the dialysis
patients was ten times lower than in the medical staff. The simultaneous
passive immunization did not lead to any impairment of the anti-HBs
titer in the dialysis patients and staff. The type of renal disease, length
of time on dialysis, hematocrit, and immunoglobulin concentration did
not influence the rate of immunization. After 12 months, 43 patients
without antibody response were vaccinated a fourth time. Sixteen of
these patients then developed anti-HBs, improving the immunization
rate from 56.5 to 71.7%. A fifth vaccination only led to seroconversion,
when brief or borderline anti-HBs could already be demonstrated
previously. In dialysis patients who fail to develop anti-HBs after three
doses of vaccine, a fourth vaccination is recommended after 12 months.
Vaccination contre l'hépatite B active de malades hémodialysés et du
personnel medical. Un cent et six nialades en insuffisance rénale
terminale et 29 personnels médicaux ont recu trois doses de vaccin
antihCpatite B a un intervalle de 0, 1, et 6 mois (Merck, Sharp et
Dohme, partie d'une étude cooperative no. 649). Les hémodialysés
chroniques (N = 99) ant recu 40 tg de vaccin (V), i.m. Les malades
urémiques, qui étaient juste au moment de commencer l'hémodialyse
chronique (N = 7), ont recu 40 tg de V, et a Ia premiere injection 3 ml
de globulines hyperimmunes (HBIG) en plus. Le personnel medical
était vaccine alternativement avec 20 g de V (N = 8), 40 tg (N = II),
40 Lg de V, et 3 ml de HBIG a Ia premiere vaccination (N = 10). Au
bout de 12 mois, 50% des hommes dialyses, 66% des femmes dialysées,
et 95% du personnel medical ont développe des anticorps anti-HBs. Le
titre des anti-HBs chez les hémodialyses Ctait dix fois plus faible que
dans le personnel medical. L'immunisation passive simultanCe n'a pas
entrainé de diminution du titre des anti-HBs chez les hémodialysés ou Ic
personnel. Le type de maladie rénale, le temps passé en hémodialyse,
l'hématocrite, et Ia concentration d'immunoglobulines n'ont pas influ-
encé Ia vitesse d'immunisation. Après 12 mois, 43 malades sans réponse
anticorps ont été vaccines une quatrième fois. Seize de ces malades ont
alors développe des anti-HBs, améliorant Ic taux d'immunisation de
56,5 a 71,7%. Une cinquieme vaccination n'a entrainC qu'une sérocon-
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version, lorsque des anti-HBs passagers ou limites pouvaient deja
auparavant étre démontrés. Chez les dialyses qui n'ont pas développe
d'anti-HBs aprés trois doses de vaccin, une quatrième vaccination est
recommandée après 12 mois.
Hepatitis B virus infection leads to chronic HBs antigen
carrier status in 60% of uremic patients. This is accompanied by
high infectivity as demonstrated by HBeAg in 70 to 90% of
patients [1—3]. HBsAg-positive patients constitute a continuous
risk of infection for the dialysis staff and their home environ-
ment. Immunogenicity and efficacy of hepatitis B vaccine were
demonstrated in groups with high risk of infection, including
homosexual men [4, 5], personnel of dialysis units [6, 7], and
dialysis patients [8]. It was shown that the development of anti-
HBs corresponds to protection from infection [7, 9]. Both
vaccines were licensed in West Germany, and a rate of immuni-
zation of over 90% was found for healthy subjects in several
investigations. In contrast, the rate of immunization of hemodi-
alysis patients varies from 89% [10], 60% [8], and 62% [11]. In
the present immunogenicity study (part of a multicentric inves-
tigation, study no. 649) the following questions were examined:
• What portion of dialysis patients are immunized and to
what degree?
• Does simultaneous passive vaccination influence the active
immunization process in patients with chronic uremia?
• What procedure is recommended in patients who do not
show any seroconversion despite triple vaccination?
Methods
One hundred six patients with terminal renal insufficiency
and 29 members of the medical staff were vaccinated with a
hepatitis B vaccine (MSD, Merck, Sharp and Dohme GmbH,
lot 802) developed by Hillemann et al [12]. Two intramuscular
injections of hepatitis B vaccine at an interval of 4 weeks and a
third injection after 6 months were given to patients and staff.
Liver enzymes were normal and no hepatitis B markers were
present in all patients. Patients, already on long-term mainte-
nance hemodialysis (group 1, N = 99) received 40 g vaccine
(V) at each interval. Uremic patients, who were just about to
start chronic hemodialysis treatment (group 2, N = 7), were
likewise given 40 jg V and in addition 3 ml hyperimmunoglobu-
lin (HBIG) at the first vaccination. Members of the medical staff
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Fig. 1. Immunization rate of patients with chronic uremia after triple
hepatitis B vaccination. Group 1 contains dialysis patients; group 2,
patients about to begin chronic hemodialysis treatment.
were alternately assigned to group 3 (20 sg V, N = 8), 4 (40 g
V, N = 11), and 5(40 g V and in addition 3m! HBIG at the first
vaccination, N = 10). When no anti-HBs antibodies could be
demonstrated after 12 months, a fourth vaccination was admin-
istered. If there was no seroconversion despite the fourth
vaccination, a fifth vaccination followed 3 months later.
Laboratory controls were carried out twice before the begin-
ning of vaccination and afterwards at intervals of 0, 1,2,3,4,5,
6, 7, 8, 9, 12, 18, 21, and 24 months. HBsAg (Auszyme), anti-
HBc (Corzyme), anti-HBs (Ausab), HBeAg and anti-HBe (Ab-
bott-HBe'M) were determined with commercially available test
systems (Abbott Laboratories, Chicago, Illinois). Sera with
positive anti-HBs findings were tested in double dilutions to the
endpoint. The limiting value was considered 2.1 times to control
determinations. The individual persons were rated as positive
when the fourfold limiting value was exceeded. Anti-HBs
positivity or seroconversion was assumed in the individual
patients and control group when anti-HBs antibodies could be
demonstrated in two consecutive controls. The following labo-
ratory values were determined each time: SGOT, SGPT, y-GT,
alkaline phosphatase, total bilirubin, IgG, IgA, and 1gM.
Results
Side effects. Fifteen patients reported the following symp-
toms: painful pressure at the injection site (1), fever (2),
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Fig. 2. Immunization rate of medical personnel in the dialysis unit after
triple immunization with different doses.
vomiting (5), nausea (2), fatigue (6), limb pains (1), headache
(3), bladder pain (1), and neck pain (1). One staff member
reported fatigue.
Deaths. Ten patients died during the observation period of 18
months. Three of these patients died within 12 months and were
therefore not considered in the evaluation. The causes of death
were: coronary heart disease with myocardia! infarction (3) or
arrhythmias (4), severe cerebral sclerosis (1), psychosis result-
ing in suicide (1), and interstitial pneumonia after kidney
transplantation (1). None of the patients had an illness resem-
bling the so-called acquired immunodeficiency syndrome
("AIDS").
Hepatitis B virus infections. During the entire observation
period, a hepatitis B virus infection occurred only in one case.
This patient, who did not show anti-HBs up to that time,
developed a hepatitis B infection of mild course within I month
after the beginning of vaccination with the occurrence of
HBsAg, HBeAg, and a moderate elevation of transaminases,
which remained below the triple normal value. Three months
after the beginning of injection, all laboratory parameters had
normalized. At the same time, anti-HBs, anti-HBe, and anti-
HBc could be demonstrated.
Immunization rate. The male dialysis patients (group lA)
developed anti-HBs in 9% after 1 month (before the second
vaccination), in 44% after 6 months (immediately before the
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third vaccination), and in 50% after 12 months. The immuniza-
tion rates of the female dialysis patients (group 1 B) were 11, 46,
and 66%, respectively (Fig. 1).
Uremic patients (group 2), who were given simultaneous
passive/active immunization for immediate protection before
the beginning of the chronic hemodialysis treatment, all showed
a seroconversion within 12 months (Fig. 1). In the control group
of the dialysis unit staff (groups 3, 4, and 5), a high immuniza-
tion rate was found independently of the vaccination scheme
(20 ,ug, 40 sg vaccine, or 40 tg vaccine and 3 ml HBIG). Only in
one patient did seroconversion not occur after administration of
20 g vaccine (Fig. 2).
Anti-HBs titers. The third vaccination led to an abrupt rise of
the anti-HBs titers which reached their maximum 1 to 2 months
later, that is, in month 7 or 8. The maximum mean geometric
titer (GMT) was 48.29 1.23 in the male dialysis patients, and
32.38 2.00 in the female dialysis patients (Fig. 3). Additional
passive immunization of patients who were just about to
commence chronic hemodialysis treatment (group 2) did not
lead to any impairment of the anti-HBs titer which averaged
181.02 8.23 after 7 months (Fig. 3). In the healthy control
group, the medical staff, the maximum mean geometric titers
were 1722.15 1.63 (GMT) (group 3), 463.73 40.3 (group 4),
and 394.80 1.55 (group 5). Compared to the dialysis patients,
the mean maximum anti-HBs titers were roughly ten times
higher in healthy subjects (Fig. 4).
Influence of sex, age, dialysis, hematocrit, kidney disease,
and immunoglobulins on anti-HBs development. After 12
months, 66% of the female dialysis patients and 50% of the male
patients had developed anti-HBs antibodies (NS). At the same
time, the immunization rate decreased with increasing age in
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Fig, 4. Anti-HBs titers in medical personnel of the dialysis unit. GMT
represents the maximum mean geometric titer.
the male patients (P < 0.01). The mean age of male dialysis
patients, who became anti-HBs positive, was 39.8 11.8 years,
and 52.8 11.7 years, when no anti-HBs occurred. Anti-HBs
was demonstrated in seven out of eight male dialysis patients
under 30 years but only in one out of nine men over 60 years.
This age-dependence could not be shown in females, where
seven out of ten dialysis patients younger than 30 years
developed anti-HBs as compared to six out of seven patients
over 60 years. The mean length of time on maintenance dialysis
and the hematocrit had no influence on the anti-HBs develop-
ment. The kind of renal disease also did not influence the
immune response to the hepatitis B vaccination with the
possible exception of men, where those with chronic glomerulo-
nephritis may have responded better (15 +18—). However, this
tendency is not statistically significant. The immunoglobulin
concentration of IgG, IgA, and 1gM in the serum also was not
correlated to the rate of immunization in either dialysis patients
or in the healthy subjects.
Fourth and fifth vaccination of patients without antibody
response. Forty-three patients in whom seroconversion had not
occurred 12 months after the beginning of vaccination received
a fourth injection. Anti-HBs then developed in 16 patients
(37%). However, a brief or borderline anti-HBs reactivity had
occurred in nine out of 16 patients during the prior 12 months,
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Fig. 3. Anti-HBs titers in patients with chronic uremia. GMT represents
the maximum mean geometric titer.
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whereas in seven patients there had been no prior reaction.
Seventeen patients who did not develop anti-HBs after the
fourth injection were vaccinated a fifth time. Only in three
patients, seroconversion occurred from this fifth vaccination.
In two of the three patients, a transient or borderline anti-HBs
titer had occurred before.
Discussion
Immunization rate. Anti-HBs antibodies developed in over
90% of the medical staff after triple vaccination. This immune
response rate was also shown for healthy subjects in other
investigations [5—7, 13—15]. In the dialysis patients, anti-HBs
occurred only in 56.5% (men 50%, women 66%). This poor
immune response is likely due to an immune deficiency of
patients with chronic uremia, which predisposes them to be-
come chronic carriers of HBs antigen as well [16]. In two
investigations, where another vaccine and vaccination schedule
were used, a comparable rate of immunization with 62 or 60% of
dialysis patients was reported [11, 8]. In contrast to these
reports and to our own results, Stevens et al [10] found a much
higher immunization rate totaling 89% (76% male and 100%
female dialysis patients) with the same vaccine, dose, and
schedule of vaccination. Our lower rate of immunization might
be partially explained by our more restrictive definition of
seroconversion, a hypothesis supported by the impressive
increase of anti-HBs antibodies after a fourth vaccination in our
patients.
In one study, female dialysis patients developed anti-HBs in a
higher percentage than men [101. However, in our investigation
and also in the one by Crosnier et al [8], this sex difference was
not statistically significant. The capacity to eliminate the HBs
antigen in a higher percentage of female patients is to be
regarded as an additional sign of a more pronounced immune
response of women. In addition, a correlation between age and
anti-HBs formation, which decreases markedly at a greater age,
has been reported [8]. In our patients, this correlation was
found only for male patients.
Simultaneous passive/active immunization. The simulta-
neous passive/active immunization does not lead to any impair-
ment of anti-HBs formation in healthy subjects [14, 15]. In our
investigation, this was also shown for patients with terminal
renal insufficiency. Immunization rate and anti-HBs titer of
chronic uremic patients did not differ in simultaneous pas-
sive/active immunization compared to active immunization
alone. However, the number of simultaneously vaccinated
patients is too small for a definitive appraisal. In addition, the
two groups differed to the extent that the simultaneously
passive/active vaccinated were still being treated conservative-
ly and were just about to start chronic hemodialysis, whereas
the active who were vaccinated had already been hemodialyzed
for months or years. Despite this limitation, a simultaneous
passive/active vaccination can be recommended in healthy
subjects and also in patients with chronic renal failure in all
situations which require an immediate protection. In patients
with chronic uremia, this problem primarily arises at the
beginning of chronic hemodialysis treatment.
Procedure in patients without antibody response. In patients
who did not show anti-HBs antibodies after 12 months, a fourth
injection then led to the appearance of anti-HBs in 37% of the
patients. If seroconversion did not occur after the fourth
vaccination, then a fifth vaccination was only successful in
three patients, two of whom had shown a brief or borderline
occurrence of anti-HBs antibodies within the previous 12
months. In dialysis patients without antibody response after
three doses of vaccine usually suggested, a fourth vaccination is
recommended, which may be instituted 12 months after the
onset of the vaccination schedule. If seroconversion does not
occur despite the fourth vaccination, a schematic fifth vaccina-
tion no longer appears to be worthwhile. A fifth vaccination
appears to be successful only when there has been prior
transient or borderline anti-HBs development. An alteration of
the vaccine dose or the vaccination schedule has to be consid-
ered for this group of patients.
Patients who only develop anti-HBs antibodies after the
fourth or fifth vaccination will probably require a booster
vaccination; this is planned for 6 months later. The suitable time
interval cannot be definitely fixed at the present time. With a
fourth vaccination, the immunization rate rises from 56.6% to a
total of 71.7% in dialysis patients. To attain a higher immuniza-
tion rate, comparable with that of healthy subjects, in prospec-
tive dialysis patients, the hepatitis B vaccination should be
carried out as soon as possible in the course of a kidney disease,
that is, before commencement of uremia with its disturbed
immune reaction.
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